The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients
and is associated with poor overall survival (OS). We analyze the characteristics, treatment …

Myelofibrosis is a chronic hematologic malignancy characterized by constitutional
symptoms, bone marrow fibrosis, extramedullary hematopoiesis resulting in splenomegaly …

Myeloproliferative neoplasms (MPN) have an inherent risk of transformation into blast phase
(MPN-BP) or accelerated phase (MPN-AP) which is characterized by presence of≥ 20% or …

Myeloproliferative neoplasms (MPN) have an inherent tendency to evolve to the blast phase
(BP), characterized by≥ 20% myeloblasts in the blood or bone marrow. MPN-BP portends a …

Leukemic transformation (LT) of myeloproliferative neoplasm (MPN) has a dismal prognosis
and is largely fatal. Mutational inactivation of TP53 is the most common somatic event in LT; …

Myelofibrosis is a rare myeloproliferative neoplasm (MPN) with high risk for progression to
acute myeloid leukemia. Our integrated genomic analysis of up to 933 myelofibrosis cases …

TP53 is the most commonly mutated gene in human cancer, typically occurring in
association with complex cytogenetics and dismal outcomes. Understanding the genetic and …

We found that in regenerative erythropoiesis, the erythroid progenitor landscape is
reshaped, and a previously undescribed progenitor population with colony-forming unit …

Abstract Treatment of acute myeloid leukemia (AML) evolving from myeloproliferative (MPN)
or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is challenging. We evaluated …